Compositions and methods for MYC messenger RNA inhibitors
AssigneesThomas Jefferson University, Bound Therapeutics, LLC
InventorsEric Wickstrom, Yuan-Yuan Jin
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods of making and using MYC mRNA antisense inhibitors. In a particular embodiment, the invention features compositions and methods useful for the treatment of a condition (e.g., cancer).
Claims21
A 2′-O, 4′-C-aminomethylene bridged nucleic acid (BNA)-deoxyribonucleic acid (DNA)-2′O, 4′-C-aminomethylene bridged nucleic acid (BNA) chimeric antisense oligonucleotide for reduction of MYC activity, wherein the BNA-DNA-BNA chimeric antisense oligonucleotide comprises SEQ ID NO:
- 2.
A kit comprising a 2′-O, 4′-C-aminomethylene bridged nucleic acid (BNA)-deoxyribonucleic acid (DNA)-2′O, 4′-C-aminomethylene bridged nucleic acid (BNA) chimeric antisense oligonucleotide which reduces MYC activity, wherein the BNA-DNA-BNA chimeric anti sense oligonucleotide comprises SEQ ID NO:
- 2, and instructional material for use thereof.
A method for reducing MYC mRNA translation in a cell, the method comprising contacting the cell with a 2′-O, 4′-C-aminomethylene bridged nucleic acid (BNA)-deoxyribonucleic acid (DNA)-2′O, 4′-C-aminomethylene bridged nucleic acid (BNA) chimeric antisense oligonucleotide comprising SEQ ID NO:
- 2.
A method of treating a condition in a subject, the method comprising administering to the subject a therapeutically effective amount of a 2′-O, 4′-C-aminomethylene bridged nucleic acid (BNA)-deoxyribonucleic acid (DNA)-2′O, 4′-C-aminomethylene bridged nucleic acid (BNA) chimeric antisense oligonucleotide for reducing MYC mRNA translation, wherein the BNA-DNA-BNA chimeric antisense oligonucleotide comprises SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.